Replies to post #16208 on Synaptogenix Inc (SNPX)

[Cyosol]

Good point. I checked the Memantine trial again and noticed the scores didn't start dropping dramatically until week 12. Maybe a longer trial without severe patients is indeed all it takes, but I still have a feeling the true value of this company won't be realized until they release positive P3 results.

Investors will definitely be more skeptical about AD drugs in general after what Biogen is trying to pull with aducanumab:

https://www.reuters.com/article/brief-biogen-completes-submission-of-bio/brief-biogen-completes-submission-of-biologics-license-application-to-fda-for-aducanumab-as-a-treatment-for-alzheimers-disease-idUSASA00W4R

P3 failed and then they ran a second test showing that they can slow down the decline by 20% in patients with an MMSE of 24-30, which barely even qualifies as mild dementia, let alone AD.